• Aliases: PLX4032, RG7204, RO5185426
    • An orally bioavailable, ATP-competitive, small molecule that selectively binds to the ATP-binding site of BRAF (V600E) kinase
    • FDA approved for the treatment of unresectable or metastatic melanoma in patients with a BRAFV600E mutation or Erdheim–Chester Disease with BRAF V600 mutation
    • Currently under investigation for other BRAF-positive cancers such as thyroid cancer, gliomas, hairy cell leukemia
    • Recommended dose: 960 mg PO twice daily
    • Half-life: 57 hours
    • Metabolism: Major CYP3A4 substrate
    • Common side effects: Arthralgia, rash, alopecia, fatigue, photosensitivity reaction, nausea, pruritus, skin papilloma
    Other topics in Targeted and Immunotherapy Agents